FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Zaremba Rabourn Amy
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/11/2020 

3. Issuer Name and Ticker or Trading Symbol

Ocuphire Pharma, Inc. [OCUP]
(Last)        (First)        (Middle)

C/O OCUPHIRE PHARMA, INC., 37000 GRAND RIVER AVE, SUITE 120
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
VP of Finance /
(Street)

FARMINGTON HILLS, MI 48335      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)6/3/2030 Common Stock 21130 $1.65 D  

Explanation of Responses:
(1) 2,113 shares vested on July 31, 2020, 2,113 shares vested on August 31, 2020, 1,056 shares vested on September 30, 2020, 1,056 shares vested on October 31, 2020 and the remaining shares vest in equal monthly installments at the end of each month from November 2020 through November 2021, with the balance vesting in December 2021, subject to continued service.

Remarks:
Exhibit 24, Power of Attorney, is attached.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Zaremba Rabourn Amy
C/O OCUPHIRE PHARMA, INC.
37000 GRAND RIVER AVE, SUITE 120
FARMINGTON HILLS, MI 48335


VP of Finance

Signatures
/s/ Emily J. Johns, by Power of Attorney11/16/2020
**Signature of Reporting PersonDate

Rexahn Pharmaceuticals (NASDAQ:REXN)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Rexahn Pharmaceuticals Charts.
Rexahn Pharmaceuticals (NASDAQ:REXN)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Rexahn Pharmaceuticals Charts.